AU757036B2 - Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies - Google Patents
Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies Download PDFInfo
- Publication number
- AU757036B2 AU757036B2 AU28799/99A AU2879999A AU757036B2 AU 757036 B2 AU757036 B2 AU 757036B2 AU 28799/99 A AU28799/99 A AU 28799/99A AU 2879999 A AU2879999 A AU 2879999A AU 757036 B2 AU757036 B2 AU 757036B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- stem cells
- embryonic stem
- embryonic
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004027 cell Anatomy 0.000 title claims description 36
- 210000000130 stem cell Anatomy 0.000 title claims description 30
- 238000002054 transplantation Methods 0.000 title description 6
- 238000009795 derivation Methods 0.000 title description 4
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 210000002459 blastocyst Anatomy 0.000 claims description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 230000001902 propagating effect Effects 0.000 claims description 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 229960003638 dopamine Drugs 0.000 claims description 5
- 230000000644 propagated effect Effects 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- -1 PDGF Proteins 0.000 claims description 4
- 230000001640 apoptogenic effect Effects 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 239000003098 androgen Substances 0.000 claims description 3
- 229940030486 androgens Drugs 0.000 claims description 3
- 229940046836 anti-estrogen Drugs 0.000 claims description 3
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 3
- 230000000708 anti-progestin effect Effects 0.000 claims description 3
- 239000003418 antiprogestin Substances 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000328 estrogen antagonist Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 2
- 210000002449 bone cell Anatomy 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 210000002308 embryonic cell Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 4
- 210000000472 morula Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000875 loss of motor control Toxicity 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000002198 morula cell Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000000251 trophoblastic cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
WO 99/43785 PCT/US99/04188 DERIVATION OP CELLS AND TISSUES FROM EMBRYONIC PRE-STEM CELLS FOR TRANSPLANTATION THERAPIES Background of the Invention The present invention relates to the derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies.
Summary of the Invention This invention relates to the use of dispersed morula cells in preference to inner cell mass (ICM) from blastocysts. The morula stage is the last pre-embryonic stage without expression of any differentiation, making these cells (pre-stem cells) all progenitors of embryonic stem cells (ESCs) later present in blastocysts.
Conversely, the ICM from the blastocyst is already differentiated from trophoblastic cells, which are by then destined to become part of the placenta.
This invention also relates to the use of chimeric introductions into pre-stem cell cultures and stem cell propagations in culture. That is, "teacher-cells" or spent media from them, that derived from other sources adults, cord blood, fetal tissues, etc.) will "teach" undifferentiated pre-stem cells how to convert to our sought-after therapeutic cell population both more rapidly and more preferentially.
This invention also relates to the identification and use of certain early markers of stem cell SUBSTITUTE SHEET (RULE 26) 2 differentiation, such as Fe++ sequestration, hemoglobin accumulation, myeloid fibers, insulin synthesis, dopamine loading, etc.
Other features and advantages of the present invention will become apparent from the following description of the invention.
Detailed Description of the Invention The present invention provides for a method of isolating and propagating a line of embryonic stem cells that originates from either morulae (pre-stem) or blastocyst (ICM stem cells). Therefore, Morula stage, undifferentiated pre-stem cells will be used as progenitors of stem cell populations. The propagated line of embryonic stem cells are then used for the purpose of transplanting 15 cells, tissues or organs.
Accordingly, in a first aspect of the present invention there is provided a method of e isolating and propagating a line of pluripotent embryonic stem cells that originates from either morulae or blastocyst comprising: propagating the stem cells in a culture medium; and adding apoptotic factors to the culture medium in order to achieve clonal properties of the propagated stem cells by eliminating contaminating members of the stem cells that did not properly differentiate.
2a The propagation of stem cells can be initiated by formation of chimeric inner cell mass cells. Chimeric ICMs will be developed from blastocysts. From such ICMs, superior stem cell cultures are derived. Preferably, the formation of chimeric inner cell mass cells comprises nuclear transplantation, mitochondrial substitution, or cytoplasmic depletion.
Preferably, at least one regulatory factor is used to propagate the line of embryonic stem cells. More preferably, the-regulatory factor is derived from "Teacher cells" or "Teacher cells'" spent culture medium. "Teacher cells" will be introduced into less differentiated pre-stem or early stage stem cells to accelerate propagation of target stem cells. Alternatively, spent media from .15 *o H:\MraR\Keep\Speci\P391 76 .dcIc 30/10/02 WO 99/43785 PCT/US99/04188 3 "teacher cells" can be used to accelerate the propagation of the target stem cells.
In a preferred embodiment, the embryonic stem cells are cultured in a medium in the presence of at least one agent or cytokine in order to differentiate into target specific cells or tissues. Preferably, the agent or cytokine is selected from the group consisting of IL-1, TNF-a, IL-6, PTH, PDGF, PGE,, cAMP, estrogens, antiestrogens, progestins, anti-progestins, cortisol, GH, androgens, 1 3
/T
3 VGEF and cyclosporin. Also preferably, the concentration of the agent or cytokine in culture medium is from about 1.0 pg/ml to about 10.0 ng/ml.
In another preferred embodiment, the target specific cells are selected from the group consisting of nerve cells, bone cells, immune cells, and pancreatic beta cells.
Techniques and parameters for the use of a broad spectrum of early stage metabolic markers are developed.
Some such markers are, for example: Fe++ sequestration, Hg accumulation, myeloid fibers, nerve growth factor, apoptotic factors, insulin synthesis, dopamine loading, hemoglobin loading, etc. Additionally, other early markers of embryonic stem cells can be identified.
Specific techniques are developed to demonstrate the foregoing. In one embodiment of the invention, embryonic stem (ES) cells are derived from either morula or blastocyst stage embryos by placing cells on fibroblast feeder layers. The colonies are evaluated for differentiation state using accepted markers. Further SUBSTITUTE SHEET (RULE 26) 4 evaluation is done by injecting ES cells into surrogate embryos to produce chimeras and evaluating the contribution of the ES cells to the adult tissues. Finally, ideal colonies of ES cells are used as nuclear donors for nuclear transplantation.
Clonal properties of the propagated stem cells are achieved by adding apoptotic factors to the culture medium to eliminate contaminating members of the stem cells that did not properly differentiate.
10 Preferably, agents are selected from the group consisting of IL-1, TNF--a, IL-6, PATH, PDGF, PGE 2 cAMP, estrogens, anti-estrogens, progestins, antiprogestins, cortisol, GH, androgens, I3/T 3 VGEF and cyclosporin.
15 Alternatively, the propagation of the line of embryonic stem cells is done in vivo by transplanting "Teacher cells" into an area sufficiently close to the embryonic stem cells to allow for at least one regulatory factor made by the teacher cells to contact the embryonic 20 cells.
Accordingly in a second aspect of the present invention there is provided a method of propagating a line of pluripotent embryonic stem cells in vivo that originates from either morulae or blastocyst comprising transplanting teacher cells into an area sufficiently close to the embryonic stem cells to allow for at least one agent or cytokine made by the teacher cells to contact the embryonic cells.
4a The presence or absence of different concentrations of calcium can be used to regulate the propagation of the line of embryonic stem cells.
Preferably, the propagated line of embryonic stem cells is grown in a three dimensional manner before being used for transplantation.
This invention will allow for the efficient, safe and commercially viable derivation of cells and tissues H:\MaraP\Keep\Speci\P39176.dcc 30/10/02 5 from embryonic pre-stem cells for transplantation therapies. Specifically, growing-out of human blastocysts at a rate greater than 50% from the 2-cell stage of the pre-embryo should be achieved. Also, efficient harvesting of either morula stage pre-stem cells and/or stem cells isolated from the inner cell mass of blastocysts should be achieved. These embryonic pre-stem and stem cell populations should preferably remain viable in culture for more than one week.
Throughout this specification and the claims, the words "comprise", "comprises" and o ."comprising" are used in a non-exclusive sense, except where the context requires otherwise.
It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.
20 0 Example 1 Clonal production of stem cells will be undertaken. These clones will respond to the ambient levels of glucose in their milieu, and in turn, insulindependent diabetes would be treated by transplanting these -stem cell lines to served by a peripheral blood supply.
the insulin secretory cells must accomplish renewal y propagation through mitogenic proliferation.
5a Example 2 Pluripotent stem cells will be isolated and directed to differentiate into hemopoietic destinies.
Therefore, tissues derived from the blood cell group or beta cells of the immune response system will be replaced in deficient patients suffering from conditions such as HIV infection, post-chemotherapy, or irradiation depletion.
Culture condition in vitro will direct the rate and degree of differentiation manifested by these pluripotent stem cells, such as The presence of "teacher cells" or certain additives to the media, e.g. cytokines.
Example 3 e H:\MaraR\Keep\Speci\P39176.dOC 30/10/02 WO 99/43785 PCT/US99/04188 6 The inherent capabilities of stem cells will be modified by formation of chimeric cell lines that incorporate "hybrid" metabolic functions that when transplanted will provide the transplant recipient with long-term relief from organ/tissue deficiencies. For instance, the production of dopamine in situ can modify neurological treatments for patients manifesting muscular rigidity and loss of motor control in disease states such as Parkinson's disease. Unlike pharmaceutical therapeutics which are partially effective temporarily, transplantation of chimeric stem cells that regulate the production dopamine and serotonergic factors will offer these patients superior outcomes.
The invention has been described in terms of preferred embodiments thereof, but is more broadly applicable as will be understood by those skilled in the art. the scope of the invention is therefore limited only by the following claims.
SUBSTITUTE SHEET (RULE 26)
Claims (9)
1. A method of isolating and propagating a line of pluripotent embryonic stem cells that originates from either morulae or blastocyst comprising: propagating the stem cells in a culture medium; and adding apoptotic factors to the culture medium in order to achieve clonal properties of the propagated stem cells by eliminating contaminating members of the stem cells that did not properly differentiate.
2. The method of claim 1, wherein the embryonic stem cells are cultured in a medium in the presence of at least one agent or cytokine in order to differentiate into specific cells or tissues.
3. The method of claim 2, wherein the agent or cytokine is selected from the group consisting of IL-1, TNF-a, IL-6, PTH, PDGF, PGE 2 cAMP, estrogens, anti-estrogens, progestins, anti-progestins, cortisol, GH, androgens, I 3 /T 3 VGEF and cyclosporin.
4. The method of claim 2, wherein the agent or cytokine is present in the culture medium at a concentration of about 1.0 pg/ml to about 10.0 ng/ml.
5. The method of claim 2, wherein the specific cells are selected from the group consisting of nerve cells, bone cells, immune cells, and pancreatic beta cells.
6. The method of claim 2, wherein the embryonic stem cell differentiation is identified by at least one marker substance that accumulates in culture medium.
7. The method of claim 6, wherein the marker substance is selected from the group consisting of an iron sequestering substance, insulin, dopamine, myeloid fibers, and hemoglobin. 8
8. The method of claim 1, wherein the embryonic stem cells are cultured in a medium in the presence or absence of varying concentrations of calcium.
9. A method of propagating a line of pluripotent embryonic stem cells in vivo that originates from either morulae or blastocyst comprising transplanting teacher cells into an area sufficiently close to the embryonic stem cells to allow for at least one agent or cytokine made by the teacher cells to contact the embryonic cells. Dated this 30th day of October 2002 15 MEDICAL COLLEGE OF HAMPTON ROADS S: By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia H:\MaraR\Kee\SpeCi\P391 7 6.doc 30/10/02
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7627398P | 1998-02-27 | 1998-02-27 | |
| US60/076273 | 1998-02-27 | ||
| PCT/US1999/004188 WO1999043785A1 (en) | 1998-02-27 | 1999-02-26 | Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2879999A AU2879999A (en) | 1999-09-15 |
| AU757036B2 true AU757036B2 (en) | 2003-01-30 |
Family
ID=22130951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU28799/99A Ceased AU757036B2 (en) | 1998-02-27 | 1999-02-26 | Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1056835A4 (en) |
| JP (1) | JP2002504362A (en) |
| AU (1) | AU757036B2 (en) |
| CA (1) | CA2320423A1 (en) |
| WO (1) | WO1999043785A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US20050042749A1 (en) | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
| US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
| US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| CA2409698C (en) | 2000-05-17 | 2010-10-26 | Geron Corporation | Neural progenitor cell populations |
| AU2002246132A1 (en) * | 2002-03-13 | 2003-09-22 | Fundacion Ivi Para El Estudio De La Reproduccion Humana (Fivier) | Method of producing cell lines |
| US9074181B2 (en) | 2005-06-22 | 2015-07-07 | Asterias Biotherapeutics, Inc. | Suspension culture of human embryonic stem cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453366A (en) * | 1990-07-26 | 1995-09-26 | Sims; Michele M. | Method of cloning bovine embryos |
| GB9308271D0 (en) * | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
| US5914268A (en) * | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
-
1999
- 1999-02-26 CA CA002320423A patent/CA2320423A1/en not_active Abandoned
- 1999-02-26 WO PCT/US1999/004188 patent/WO1999043785A1/en not_active Ceased
- 1999-02-26 AU AU28799/99A patent/AU757036B2/en not_active Ceased
- 1999-02-26 EP EP99909633A patent/EP1056835A4/en not_active Withdrawn
- 1999-02-26 JP JP2000533525A patent/JP2002504362A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1056835A4 (en) | 2003-01-15 |
| CA2320423A1 (en) | 1999-09-02 |
| AU2879999A (en) | 1999-09-15 |
| EP1056835A1 (en) | 2000-12-06 |
| JP2002504362A (en) | 2002-02-12 |
| WO1999043785A1 (en) | 1999-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100432220C (en) | Keratinocytes useful as bioactive substances in wound therapy | |
| Yokoo et al. | Xenobiotic kidney organogenesis from human mesenchymal stem cells using a growing rodent embryo | |
| Takaku et al. | In vivo cell tracking by bioluminescence imaging after transplantation of bioengineered cell sheets to the knee joint | |
| Fossum et al. | Isolation and in vitro cultivation of human urothelial cells from bladder washings of adult patients and children | |
| KR20150125926A (en) | Human and large-mammal lung bioreactor | |
| PT91676A (en) | THREE-DIMENSIONAL CELL AND TISSUE CULTURE SYSTEM | |
| CN105112362B (en) | A kind of serum free medium of placenta mesenchyma stem cell and preparation method thereof | |
| AU757036B2 (en) | Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies | |
| KR101335884B1 (en) | Synthetic cornea from retinal stem cells | |
| Feng et al. | Fertilization and early embryology: Effect of different co-culture systems in early human embryo development | |
| US20030143737A1 (en) | Long-term cell-culture compositions and genetically modified animals derived therefrom | |
| Yu et al. | Optimal stem cell transporting conditions to maintain cell viability and characteristics | |
| ATE524542T1 (en) | SCHWANN CELLS FROM BONE MARROW SUPPORTING CELLS | |
| Iwata et al. | Cell sheets for periodontal tissue engineering | |
| US20020159975A1 (en) | Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies | |
| Yuh et al. | The effects of various antioxidants on the development of parthenogenetic porcine embryos | |
| Ferguson et al. | 136 evidence of a direct effect of P4 on IVF-derived bovine 8-cell embryos | |
| US20070207542A1 (en) | Manipulation of oxygen tension during in vitro follicle culture | |
| US20110250236A1 (en) | Stem cells derived from the carotid body and uses thereof | |
| Poleszczuk et al. | 148 AN EFFECT OF MELATONIN ON DEVELOPMENT OF BOVINE EMBRYOS CULTURED IN VITRO UNDER OPTIMAL OR ENHANCED OXYGEN TENSIONS | |
| Suckow et al. | Tissue distribution of fetal liver cells following in utero transplantation in mice | |
| UA159602U (en) | METHOD FOR OBTAINING A MODIFIED CULTURE OF UMBILICAL CORD MESENCHYMATIC STEM CELLS | |
| Ock et al. | 145 COMPARISON OF DEVELOPMENT AND QUALITY OF PORCINE EMBRYOS CULTURED IN DIFFERENT OXYGEN CONCENTRATIONS | |
| AU779273B2 (en) | Long-term cell culture compositions and genetically modified animals derived therefrom | |
| De La Torre-Sanchez et al. | 135 REGULATION OF GLUCOSE METABOLISM TO DECREASE LIPID CONTENT OF IN VIRTO-PRODUCED BOVINE EMBRYOS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |